Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Danilov on Utility of Rituximab Biosimilars in CLL

December 14th 2019

Alexey V. Danilov, MD, PhD, discusses the utility of rituximab biosimilars in chronic lymphocytic leukemia.

Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL

December 10th 2019

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up

December 10th 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.

Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL

December 9th 2019

Benjamin L. Lampson, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, discusses preliminary safety and efficacy results from a phase II study of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Liso-Cel Continues to Show Promise in Relapsed/Refractory CLL/SLL

December 9th 2019

The CD19-directed CAR T-cell therapy lisocabtagene maraleucel showed promising clinical activity and manageable toxicity in heavily pretreated patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma, all of whom had progressed on ibrutinib.

Zanubrutinib Effective in CLL/SLL, Regardless of Del(17p) Status

December 9th 2019

The BTK inhibitor zanubrutinib continues to demonstrate high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of the presence of high-risk cytogenetics.

Dr. Seymour on the 4-Year Update of the MURANO Trial in CLL

December 9th 2019

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the 4-year update of the phase III MURANO trial in chronic lymphocytic leukemia (CLL).

Novel Triplet Shows Early Promise for Pretreated CLL

December 8th 2019

The triplet of umbralisib, ublituximab, and venetoclax induced a complete remission rate of 44% as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Tam on Results of the CAPTIVATE Trial in CLL

December 8th 2019

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Acalabrutinib Triplet Highly Active in Frontline CLL

December 8th 2019

The triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva; AVO) is highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in CLL

December 8th 2019

With extended follow-up, progression-free survival continues to be superior with the combination of ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab for patients ≤70 years with previously untreated chronic lymphocytic leukemia.

Frontline Ibrutinib/Venetoclax Combo Leads to High Rates of Undetectable MRD in CLL

December 8th 2019

The first-line combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) led to a 75% undetectable minimal residual disease rate in peripheral blood and 72% in bone marrow in patients with chronic lymphocytic leukemia.

Acalabrutinib Alone or in Combination Improves PFS in Frontline CLL

December 7th 2019

Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Wierda on Chemoimmunotherapy in CLL

December 6th 2019

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

New BTK Agents and Combinations Are on the Horizon for B-cell Malignancies

December 5th 2019

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

Chemoimmunotherapy Role in CLL Shifting With Rise of Novel Agents

December 4th 2019

Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Cohen on the ELEVATE-TN Trial in CLL

December 3rd 2019

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, co-director, Lymphoma Program, and medical director, Infusion Services, Winship Cancer Institute of Emory University, discusses the design of the phase III ELEVATE-TN trial in chronic lymphocytic leukemia (CLL).

Dr. Mato on Ibrutinib Versus Acalabrutinib in CLL

November 23rd 2019

Anthony R. Mato, MD, MSCE, discusses differences between the use of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Furman on Frontline Treatment Selection in CLL

November 22nd 2019

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

FDA Approves Acalabrutinib for CLL

November 21st 2019

The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.